Skip to main content

Sophia Cenac Weinmann

Associate Professor of Medicine
Medicine, Rheumatology and Immunology

Scholarly Works


Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.

Journal article Rheumatology (Oxford, England) · December 2019 Immune checkpoint inhibitors are novel biologic agents to treat cancer by inhibiting the regulatory interactions that limit T cell cytotoxicity to tumours. Current agents target either CTLA-4 or the PD-1/PD-L1 axis. Because checkpoints may also regulate au ... Full text Open Access Cite